http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Soligenix, Inc. (SNGX) Invited to Submit BARDA Contract Proposal for Development of Thermostabilized Subunit Vaccines for Sudan Ebola and Marburg Viruses
-
Soligenix Invited to Submit BARDA Contract Proposal for Development of Thermostabilized Subunit Vaccines for Sudan Ebola and Marburg Viruses
-
Soligenix Announces Formation of Psoriasis Medical Advisory Board
-
New to The Street TV Announces its 399th Show, Featuring Five Corporate Interviews, Airing on the Fox Business Network, Tonight, Monday, October 24, 2022, at 10:30 PM PT
-
New to The Street / Newsmax TV Announces its Nine Corporate Interviews for This Week's TV Broadcast, Episode #398, October 23, 2022, 10-11 AM ET
-
Soligenix Announces Adjournment of Annual Meeting and Information for Reconvened Meeting
-
UPDATE: New to The Street to Feature Soligenix Appearances on Its Syndicated Televised Outlets
-
New to The Street to Feature Soligenix Appearances on Its Syndicated Televised Outlets
-
Soligenix Announces Partial Adjournment of Annual Meeting and Information for Reconvened Annual Meeting
-
Soligenix to Present at the H.C. Wainwright 24th Annual Global Investment Conference
-
Soligenix, Inc. (SNGX) Awarded $2.6 Million FDA Orphan Products Development Grant for Expanded Study of HyBryte
-
U.S. Food and Drug Administration Awards $2.6 Million Orphan Products Development Grant for Expanded Study of HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma
-
Presenting on the Emerging Growth Conference on August 17 Register Now
-
Soligenix Announces Recent Accomplishments And Second Quarter 2022 Financial Results
-
Soligenix, Inc. (SNGX) Announces FDA Agreement on Initial Pediatric Study Plan for HyBryte
-
Soligenix Receives Agreement from FDA on Initial Pediatric Study Plan for HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma
-
Soligenix, Inc. (SNGX) and SERB Pharmaceuticals Partner for Supply of Ricin Antigen
-
Soligenix Announces Strategic Partnership with SERB Pharmaceuticals to Supply its Novel Ricin Antigen
-
Soligenix (SNGX) Announces Publication of HyBryte Phase 3 FLASH Study for Treatment of Cutaneous T-Cell Lymphoma
-
HyBryte™ Phase 3 FLASH Study for the Treatment of Cutaneous T-Cell Lymphoma Published in JAMA Dermatology
-
Soligenix, Inc. (SNGX) Receives FDA IND Clearance for Phase 2 Clinical Trial of Synthetic Hypericin in the Treatment of Psoriasis
-
Soligenix Receives FDA IND Clearance for Phase 2 Clinical Trial of Synthetic Hypericin in the Treatment of Psoriasis
-
Soligenix, Inc. (SNGX) Reports Successful Protection using a Bivalent Thermostabilized Filovirus Vaccine
-
Soligenix Announces Successful Protection using a Bivalent Thermostabilized Filovirus Vaccine
-
Key Binding Characteristics of Dusquetide to Important Intracellular Protein Identified
-
Soligenix Receives US Patent Allowance for its Thermostabilized Vaccine Platform
-
Soligenix to Present at the H.C. Wainwright Global Investment Conference
-
Soligenix Announces Recent Accomplishments And First Quarter 2022 Financial Results
-
Soligenix (SNGX) Receives $1.4M in Non-Dilutive Government Funding
-
Soligenix Receives $1.4M in Non-Dilutive Government Funding
-
Soligenix Announces Recent Accomplishments And Year-End 2021 Financial Results
-
Soligenix's (SNGX) CiVax Boosts Neutralizing Activity against SARS-CoV-2, including Delta and Omicron
-
Soligenix COVID-19 Vaccine, CiVax™, Boosts Neutralizing Activity against SARS-CoV-2, including Delta and Omicron
-
Soligenix to Present at the Q1 Virtual Investor Summit
-
Soligenix, Inc. to Present at the Q1 Virtual Investor Summit
-
Soligenix to Present at the 2022 BIO CEO & Investor Conference
-
Soligenix Corporate Update Letter - Key Highlights and Upcoming Catalysts
-
Soligenix to Present at Upcoming Investor Conferences
-
Soligenix, Inc. (SNGX) Announces Dusquetide Demonstrates Positive Anti-tumor Efficacy in Multiple Nonclinical Animal Studies
-
Dusquetide Demonstrates Positive Anti-tumor Efficacy in Multiple Nonclinical Animal Studies
-
Soligenix, Inc. (SNGX) Reports Successful Protection from Sudan Ebolavirus with a Bivalent Thermostabilized Filovirus Vaccine
-
Soligenix Announces Successful Protection using a Bivalent Thermostabilized Filovirus Vaccine
-
Soligenix Announces Recent Accomplishments And Third Quarter 2021 Financial Results
-
Soligenix, Inc. (SNGX) Granted UK Pediatric Investigational Plan Waiver for HyBryte in CTCL
-
Soligenix Granted Pediatric Investigational Plan Waiver for HyBryte™ in CTCL in the United Kingdom
-
Soligenix, Inc. (SNGX) Announces Publication Demonstrating Enduring Protection of its Thermostable RiVax Vaccine
-
Soligenix Announces Publication Demonstrating Enduring Protection of its Thermostable RiVax® Vaccine
-
Thermostable Vaccine Technology Platform to be Presented at the 6th International Conference on Vaccines Research and Development
-
HyBryte™ FLASH Study Selected as a 'Top Poster' Winner for Presentation at the National Organization for Rare Disorders' Rare Diseases and Orphan Products Breakthrough Summit
-
Soligenix (SNGX) Announces Accelerated Publication Demonstrating Efficacy and Broad Neutralizing Activity of its COVID-19 Vaccine in Non-Human Primates
